PCI in the patient with in stent restenosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
{{Editor Help}} | {{Editor Help}} | ||
==Background== | |||
In-stent restenosis (ISR) is the most frequent late complication of [[stent]] implantation. It occurs when there is a reoccurrence of [[stenosis]] around a lesion that has been treated with a [[stent]]. Although ISR typically occurs in 10-80% of treated [[lesions]], its incidence has been dramatically reduced by the development of [[drug-eluting stents]]. | |||
| Line 17: | Line 19: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
{{mdr}} | {{mdr}} | ||
[[Media:Example.ogg]] | |||
Revision as of 20:02, 30 April 2010
| Cardiology Network |
 Discuss PCI in the patient with in stent restenosis further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: Laura Nasrallah, M.D.; David M. Leder, M.D.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Background
In-stent restenosis (ISR) is the most frequent late complication of stent implantation. It occurs when there is a reoccurrence of stenosis around a lesion that has been treated with a stent. Although ISR typically occurs in 10-80% of treated lesions, its incidence has been dramatically reduced by the development of drug-eluting stents.